Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II

NCT05505916 is registered in ClinicalTrials.gov with KalVista Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT05505916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05505916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 24, 2022
Completion date
May 27, 2026
Enrollment
145 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema